Last reviewed · How we verify
NCT05168631
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
trial in Neuroendocrine Tumors in 88 participants. Participants enrolled and being followed up; not accepting new ones.
15 March 2025
Quick facts
| Lead sponsor | Latin American Cooperative Oncology Group |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 88 |
| Start date | 16 May 2020 |
| Primary completion | 15 March 2025 |
| Estimated completion | 15 March 2025 |
| Sites | 7 locations across Brazil, Peru |
Conditions studied
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
- Carcinoma;Endocrine — all drugs for Carcinoma;Endocrine →
Sponsor
Latin American Cooperative Oncology Group
Who can join
18 and older, any sex, with Neuroendocrine Tumors or Carcinoma;Endocrine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multicenter retrospective longitudinal analytical study of patients with neuroendocrine tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05168631
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuroendocrine Tumors
Currently open trials in the same condition.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
- NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
- NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
- NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting
Other Latin American Cooperative Oncology Group trials
Trials by the same sponsor.
- NCT07192991 — Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America · not yet recruiting
- NCT06822543 — A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastas · Phase 2 · recruiting
- NCT06527690 — Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficien · Phase 2 · withdrawn
- NCT06279442 — Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort · recruiting
- NCT06014580 — Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05168631 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Latin American Cooperative Oncology Group
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05168631.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing